SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $38,147.88 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 7,393 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.16, for a total value of $38,147.88. Following the completion of the transaction, the insider directly owned 233,387 shares in the company, valued at approximately $1,204,276.92. This represents a 3.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total value of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total value of $24,750.00.
• On Monday, April 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.82, for a total value of $24,100.00.
• On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total value of $3,161.60.
• On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total transaction of $7,936.00.
• On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $20,944.00.
• On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total transaction of $17,433.00.
• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,152.94.
• On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.

SOPHiA GENETICS Price Performance

Shares of SOPH traded up $0.10 during trading hours on Tuesday, reaching $5.44. 284,563 shares of the stock traded hands, compared to its average volume of 187,273. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS SA has a 52-week low of $2.92 and a 52-week high of $6.30. The company’s 50-day moving average price is $5.12 and its two-hundred day moving average price is $4.96. The company has a market cap of $456.36 million, a P/E ratio of -10.46 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors have recently added to or reduced their stakes in the company. First Dallas Securities Inc. bought a new stake in SOPHiA GENETICS in the 1st quarter worth approximately $50,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS in the third quarter valued at $49,000. Perkins Capital Management Inc. bought a new stake in SOPHiA GENETICS in the fourth quarter worth $49,000. Quadrature Capital Ltd purchased a new stake in SOPHiA GENETICS during the fourth quarter valued at $54,000. Finally, XTX Topco Ltd purchased a new stake in SOPHiA GENETICS during the fourth quarter valued at $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on SOPH shares. BTIG Research reaffirmed a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.